Jefferies Initiates Coverage On Zenas BioPharma with Buy Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Jefferies has initiated coverage on Zenas BioPharma with a Buy rating and set a price target of $35.
October 08, 2024 | 6:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on Zenas BioPharma with a Buy rating and a price target of $35, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a reputable firm like Jefferies is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100